Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nolato AB (publ) (NOLA-B.ST)
Torekov, SE
Nolato AB (publ) is a Swedish enterprise that specializes in the creation, manufacturing, and commercialization of polymer-based products, utilizing plastics, silicones, and thermoplastic elastomers. Its extensive portfolio serves a diverse array of industries, including medical technology, pharmaceuticals, consumer electronics, telecommunications, automotive, and other industrial applications. The company maintains a global presence, operating in North America, various European countries (including Sweden), and Asia. Its offerings are wide-ranging: For clinical, chemical, forensic, research, and industrial testing laboratories, Nolato provides both disposable and reusable labware, encompassing products like pipette tips, deep-well plates, microtubes, and PCR items. It also supplies primary pharmaceutical packaging solutions designed for solids, creams, and ophthalmic preparations, along with customized production services. In the electronics sector, Nolato engineers, develops, and produces advanced components, subsystems, and complete packaged electronic devices. These include specialized items such as laser application parts and ceramics, consumer gadgets like fitness trackers, loudspeaker systems, thermostats, webcams, and heating elements for vaporizers. Furthermore, the company contributes to the automotive industry and delivers specialized solutions for electromagnetic interference (EMI) shielding, thermal management, and silicone-based sealing and damping. It also furnishes plastic components and assemblies for food processing equipment, such as coffee machines and blenders. Established in 1938, the company was originally known as Nordiska Latexfabriken i Torekov AB before officially changing its name to Nolato AB (publ) in 1982. Its corporate headquarters are located in Torekov, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.20% | +1.77% | -3.84% | -3.65% | -20.50% | -18.24% | -16.71% | -15.04% | -43.85% | +141.23% | +261.32% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Conglomerates: +6.1%-2.1% Q1'26: -3.9% (vs Q1'25)
-
EPS growth Conglomerates: +16.9%+18.0% ★ Q1'26: -9.5% (vs Q1'25)
-
FCF margin FCF growth · Conglomerates: +35.9%+11.0% ★ Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Conglomerates: +9.0%+10.8% ★ Q1'26: +10.5% (vs Q1'25)
-
ROIC Conglomerates: +4.7%+12.4% ★ Q1'26: +12.0% (vs Q1'25)
-
Share dilution Conglomerates: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Conglomerates: 1.28×0.91× ★ Q1'26: 0.68× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 4 Rev. Ana. 3 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.73B
est: 4.54B (+4.1%)
|
4.45B
est: 4.32B (+3.0%)
|
6.72B
est: 6.56B (+2.4%)
|
8.10B
est: 8.28B (-2.1%)
|
7.92B
est: 7.67B (+3.3%)
|
9.36B
est: 9.45B (-1.0%)
|
11.61B
est: 11.55B (+0.5%)
|
10.77B
est: 10.90B (-1.2%)
|
9.55B
est: 9.47B (+0.8%)
|
9.66B
est: 9.61B (+0.6%)
|
9.46B
est: 9.47B (-0.1%)
|
9.71B
9.64B – 9.89B
+2.5% YoY
|
10.52B
10.30B – 10.94B
+8.3% YoY
|
11.27B
11.23B – 11.31B
+7.1% YoY
|
11.55B
11.38B – 11.89B
+2.5% YoY
|
| EBITDA |
740.00M
est: 679.22M (+8.9%)
|
636.00M
est: 645.61M (-1.5%)
|
997.00M
est: 981.41M (+1.6%)
|
1.19B
est: 1.24B (-3.6%)
|
1.25B
est: 1.15B (+9.1%)
|
1.46B
est: 1.41B (+3.2%)
|
1.92B
est: 1.73B (+10.9%)
|
1.48B
est: 1.63B (-9.5%)
|
1.28B
est: 1.71B (-25.0%)
|
1.51B
est: 1.73B (-13.1%)
|
1.59B
est: 1.71B (-6.9%)
|
1.75B
1.74B – 1.78B
+2.5% YoY
|
1.90B
1.86B – 1.98B
+8.3% YoY
|
2.03B
2.03B – 2.04B
+7.1% YoY
|
2.08B
2.05B – 2.15B
+2.5% YoY
|
| EBIT |
560.00M
est: 443.57M (+26.2%)
|
443.00M
est: 421.63M (+5.1%)
|
742.00M
est: 640.92M (+15.8%)
|
929.00M
est: 808.46M (+14.9%)
|
875.00M
est: 748.89M (+16.8%)
|
1.05B
est: 923.33M (+13.9%)
|
1.44B
est: 1.13B (+27.9%)
|
931.00M
est: 1.06B (-12.6%)
|
686.00M
est: 917.41M (-25.2%)
|
903.00M
est: 930.46M (-3.0%)
|
1.02B
est: 917.12M (+11.7%)
|
940.46M
933.94M – 957.32M
+2.5% YoY
|
1.02B
997.77M – 1.06B
+8.3% YoY
|
1.09B
1.09B – 1.10B
+7.1% YoY
|
1.12B
1.10B – 1.15B
+2.5% YoY
|
| Net Income |
420.00M
est: 435.99M (-3.7%)
|
336.00M
est: 346.53M (-3.0%)
|
572.00M
est: 549.89M (+4.0%)
|
722.00M
est: 744.80M (-3.1%)
|
703.00M
est: 699.03M (+0.6%)
|
806.00M
est: 853.39M (-5.6%)
|
1.16B
est: 1.02B (+14.2%)
|
697.00M
est: 694.80M (+0.3%)
|
435.00M
est: 475.00M (-8.4%)
|
658.00M
est: 681.58M (-3.5%)
|
777.00M
est: 835.62M (-7.0%)
|
843.52M
788.45M – 854.30M
+0.9% YoY
|
1.01B
927.91M – 1.03B
+19.9% YoY
|
1.14B
997.08M – 1.16B
+13.2% YoY
|
1.10B
1.08B – 1.14B
-4.2% YoY
|
| SGA |
279.00M
est: 263.59M (+5.8%)
|
285.00M
est: 250.55M (+13.7%)
|
321.00M
est: 380.87M (-15.7%)
|
336.00M
est: 480.43M (-30.1%)
|
357.00M
est: 445.03M (-19.8%)
|
431.00M
est: 548.69M (-21.4%)
|
535.00M
est: 670.28M (-20.2%)
|
602.00M
est: 632.85M (-4.9%)
|
689.00M
est: 613.61M (+12.3%)
|
677.00M
est: 622.34M (+8.8%)
|
754.00M
est: 613.42M (+22.9%)
|
629.03M
624.66M – 640.30M
+2.5% YoY
|
681.51M
667.36M – 708.92M
+8.3% YoY
|
729.86M
727.29M – 732.42M
+7.1% YoY
|
747.89M
737.32M – 769.97M
+2.5% YoY
|
| EPS |
1.60
est: 1.62 (-1.1%)
|
1.28
est: 1.29 (-0.5%)
|
2.17
est: 2.04 (+6.3%)
|
2.74
est: 2.76 (-0.9%)
|
2.66
est: 2.60 (+2.5%)
|
3.03
est: 3.17 (-4.4%)
|
4.32
est: 3.77 (+14.5%)
|
2.59
est: 2.58 (+0.4%)
|
1.61
est: 1.76 (-8.7%)
|
2.44
est: 2.51 (-2.6%)
|
2.88
est: 3.11 (-7.4%)
|
3.00
2.93 – 3.17
-3.6% YoY
|
3.55
3.44 – 3.81
+18.5% YoY
|
3.94
3.70 – 4.31
+11.0% YoY
|
4.07
4.00 – 4.23
+3.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-05 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-30 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.06% | 2.16M | 0.30% |
| 2 | iShares MSCI Europe Small-Cap ETF IEUS | 0.06% | 109.5K | 0.41% |
| 3 | State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR Acc ZPRX.DE | 0.04% | 327.3K | 0.30% |
| 4 | Avantis International Small Cap Equity ETF AVDS | 0.04% | 126.7K | 0.30% |
| 5 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.03% | 62.8K | 0.83% |
| 6 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.03% | 3.78M | 0.40% |
| 7 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.03% | 3.75M | 0.06% |
| 8 | Dimensional - International Small Cap ETF DFIS | 0.02% | 1.16M | 0.39% |
| 9 | Avantis International Small Cap Value ETF AVDV | 0.01% | 2.70M | 0.36% |
| 10 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.01% | 44.7K | 0.23% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christer Wahlquist | President, Chief Executive Officer & Interim President of Industrial Solutions | 15M | male |
| Per-Ola Holmstrom | Executive Vice President & Chief Financial Officer | 8M | male |
| Glenn Svedberg | Group Sustainability Director & Technology Director | — | male |
| Henrik Enoksson | Managing Director of Nolato Lövepac | — | — |
| Johan Iveberg | President of Medical Solutions | — | male |
| Mats Håkansson | Group Corporation Communication Mang. | — | male |
| Olof Pettersson | Managing Director of Nolato Gota & Nolato Plastteknik | — | — |
| Anders Willman | Managing Director of Nolato Polymer | — | — |
| Thomas Hofflander | Managing Director of Nolato Beijing Medical & Nolato Beijing | — | — |
| Dan Wong | Managing Director of Nolato Lovepac Converting | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NOLA-B.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
